Advertisement

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil and Markus Raderer for the AGMT Investigators

You do not have access to the full text of this article, the first page of the PDF of this article appears below.

PDF extract preview